ARDX biotech catalysts & pipeline

ARDELYX INC · Data as of 2026-09-08

Upcoming catalysts

RDX10531 — IND submission

H2 2026

The company is currently completing pre-clinical development activities in advance of an Investigational New Drug submission to the FDA in the second half of 2026 and initiation of a Phase 1 clinical trial thereafter.

Source filing

IBSRELA (tenapanor) — Topline data

H2 2027

The Company is on track to complete enrollment by the end of 2026 and to announce top-line data in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar